PBI-01207
Neurodegenerative Diseases
Pre-clinicalActive
Key Facts
About Phoenix Biotechnology
Phoenix Biotechnology is a private, clinical-stage company leveraging the bioactive compounds of the Nerium oleander plant to develop novel therapeutics for oncology, virology, and neurodegeneration. Its lead candidate, PBI-05204, has progressed to Phase II trials for glioblastoma and other cancers, demonstrating a unique mechanism of action involving FGF-2 inhibition and immune modulation. The company's strategy targets high-unmet-need indications with a natural product-derived platform, aiming for safer, more affordable treatments, though it faces challenges typical of botanical drug development and early-stage biotechs.
View full company profileOther Neurodegenerative Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | Modulo Bio | Discovery |
| Therapeutic Target Discovery Platform | ValtedSeq | Discovery |
| Undisclosed Neurology Program(s) | Base4 | Preclinical |
| Platform Application for Neurodegenerative Diseases | ALTUCELL | Pre-clinical/Research |
| OGG1 Activator Program | Luciole Pharmaceuticals | Pre-clinical |
| Lysosome Biology Program | Talisman Therapeutics | Preclinical |
| Microglial Health Program | Talisman Therapeutics | Preclinical |
| HSF1 Activator Program | Sisu Pharma | Pre-clinical |
| Platform-derived candidates | VRG Therapeutics | Pre-clinical |
| Neurodegenerative Biomarkers R&D | Firalis | Development |
| Neurodegeneration Pipeline | Origenis | Preclinical |
| Enhanced Brain Delivery (EBD™) Platform | Acumen Pharmaceuticals | Preclinical |